BioCity based XenoGesis’ Global Head of Business Development, Dr Rachel Hemsley has joined the University of Oxford’s Medical Sciences Experts in Residence (ExIR) scheme. The Experts in Residence programme is managed by the Medical Science Division’s Translational Research Office, Business Development & Partnering team and Oxford University Innovation. It aims to...
MediCity, Nottingham based Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, today announces that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline. John von Benecke has...
Supporting the discovery and development of new therapeutics during the pandemic Nottingham-based contract research organisations (CROs) have strengthened their existing links to work together and support the discovery and development of new therapeutics during the pandemic. Many businesses have been impacted by the restrictions on the movement...
BioCity 2019 Accelerator programme graduate company, Myndr, has secured six-figure funding from the government’s business innovation programme. Myndr, which is based in Newcastle, has received £300k investment from Innovate UK to expand its proposition. Founded by Lizzy Hodcroft and Emma Reilly, Myndr aims to create an anonymous platform,...
Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) have invested £500K in significantly expanding their tablet manufacturing capabilities with the addition of tablet processing equipment for wet granulation, roller compaction, tablet compression, hardness testing, dedusting, weight sorting and tablet coating throughout 2019...
Nottingham is taking part for the first time in an annual event to document nature and needs your help...
Nottingham-based leading independent DMPK provider, XenoGesis, has been awarded the prestigious Queen’s Award for Enterprise, International Trade, in recognition of its outstanding year-on-year export growth. XenoGesis is one of only three Nottinghamshire-based companies and 12 in the whole of the East Midlands to receive a Queen’s...
Excellerate Bioscience is delighted that a close relationship with Omass Therapeutics, built over 18 months, has helped contribute to their success in securing extended series A funding. During this period, Excellerate assembled a dedicated team of expert pharmacologists focussed exclusively on driving forward the Omass...
BioAscent is privileged to partner with the University of Glasgow, which is set to host a major COVID-19 testing facility to support the UK and Scottish Governments and NHS efforts against the coronavirus. The facility is part of a series of measures to increase testing in...
The full Alantra Pharma Fast 50 report is now available online and features an in-depth profile of BioAscent, which was recognised as the UK’s fastest-growing drug discovery CRO, coming out top of the outsourcing category and third in the overall listing. Alantra’s annual report on the...